Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1259 • ACR Convergence 2021
Association of SLE Responder Index (SRI) Attainment and Long-term Clinical Outcomes
Kathryn Connelly¹, Rangi Kandane-Rathnayake¹, Alberta Hoi², Worawit Louthrenoo³, Laniyati Hamijoyo⁴, Jiacai Cho⁵, Aisha Lateef⁶, Shue-Fen Luo⁷, Yeong-Jian Wu⁸, C.S. Lau⁹, YI-HSING CHEN¹⁰, Sandra Navarra¹¹, Leonid Zamora¹¹, Zhanguo Li¹², Yuan An¹², Sargunan Sockalingam¹³, Yanjie Hao¹⁴, Zhuoli Zhang¹⁴, Madelynn Chan¹⁵, Yasuhiro Katsumata¹⁶, Masayoshi Harigai¹⁶, Shereen Oon¹⁷, Sang-Cheol Bae¹⁸, Sean O’Neill¹⁹, Kathryn Gibson¹⁹, Jun Kikuchi²⁰, B.M.D.B. Basnayake²¹, Tsutomu Takeuchi²², Kristine (Pek Ling) Ng²³, Fiona Goldblatt²⁴, Annie Law²⁵, Nicola Tugnet²⁶, Yoshiya Tanaka²⁷, Sunil Kumar²⁸, Michael Tee²⁹, Jin Yu Tan³⁰, Chetan Karyekar³¹, Mandana Nikpour³², Vera Golder¹ and Eric Morand³³, ¹Monash University, Clayton, Australia, ²Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia, ³Maharaj Nakorn Chiangmai, Chiang Mai, Thailand, ⁴University of Padjadjaran, Bandung, Indonesia, ⁵National University Health System (NUHS), Singapore, Singapore, ⁶National University Hospital, Singapore, Singapore, ⁷Chang Gung Memorial Hospital, Taipei, Taiwan, ⁸Chang Gung Memorial Hospital, Taoyuan County, Taiwan, ⁹University of Hong Kong, Hong Kong, Hong Kong, ¹⁰Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ¹¹University of Santo Tomas Hospital, Manila, Philippines, ¹²People's Hospital, Peking University Health Science Center, Beijing, China (People's Republic), ¹³University of Malaya, Kuala Lumpur, Malaysia, ¹⁴Peking University First Hospital, Beijing, China (People's Republic), ¹⁵Tan Tock Seng Hospital, Singapore, Singapore, ¹⁶Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ¹⁷Melbourne Health, Parkville, Australia, ¹⁸Hanyang University Medical Center, Seoul, Republic of Korea, ¹⁹Liverpool Hospital, Sydney, Australia, ²⁰Keio University School of Medicine, Tokyo, Japan, ²¹Teaching (General) Hospital, Kandy, Sri Lanka, ²²Div. Rheumatology, Keio University, Tokyo, Japan, ²³North Shore Hospital, Auckland, New Zealand, ²⁴Flinders Medical Centre, Adelaide, Australia, ²⁵Singhealth, Singapore, Singapore, ²⁶Auckland District Health Board, Auckland, New Zealand, ²⁷University of Occupational and Environmental Health, Kitakyushu, Japan, ²⁸Counties Manukau Health, Auckland, New Zealand, ²⁹University of the Philippines, Quezon City, Philippines, ³⁰Janssen Asia Pacific, Singapore, Singapore, ³¹Janssen R&D, Spring House, PA, ³²University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ³³School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia
Background/Purpose: The SLE Responder Index (SRI) is a composite responder definition employed as a clinical trial endpoint in SLE. Despite its widespread adoption, recent discrepant…
Abstract Number: 1275 • ACR Convergence 2021
Digital Solution for Collection of Patient-reported Outcome Measures in Patients with Systemic Lupus Erythematosus: A Randomised, Crossover, Agreement Study
Line Uhrenholt¹, Simone Høstgaard², Julie Pedersen², Robin Christensen³, Lene Dreyer¹, Henrik Leffers⁴, Peter C Taylor⁵, Vibeke Strand⁶, Sren Jacobsen⁴, Anne Voss⁷, Jon Gregersen⁸ and Salome Kristensen¹, ¹Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ²Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, ³Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen & Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Copenhagen, Denmark, ⁴Copenhagen Lupus and Vasculitis Clinic, Centre for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ⁵University of Oxford, Oxford, United Kingdom, ⁶Stanford University School of Medicine, Portola Valley, CA, ⁷Department of Rheumatology, Odense University Hospital, Odense C, Denmark, ⁸Department of Nephrology, Aalborg University Hospital, Aalborg, Denmark, Aalborg, Denmark
Background/Purpose: Patient-reported outcome measures (PROMs) provide the physician with an important insight into the patients’ perception of lupus disease activity. Technology and the widespread use…
Abstract Number: 1291 • ACR Convergence 2021
Risk of Bleeding-related Complications After Kidney Biopsy in Patients with Systemic Lupus Erythematosus
Eun Song Kang¹, Ji Seon Oh², Soo Min Ahn¹, Yong Gil Kim¹, Chang-Keun Lee¹, Bin Yoo³ and Seokchan Hong³, ¹Asan Medical Center, Seoul, Republic of Korea, ²Asan Medical Center, Ulsan, Republic of Korea, ³Asan Medical Center, Seoul, South Korea
Background/Purpose: Kidney biopsy is essential for the diagnosis and classification of lupus nephritis in patients with systemic lupus erythematosus (SLE). Even though the risk of…
Abstract Number: 1423 • ACR Convergence 2021
Ability of Soluble Immune Mediators and SLE-associated Autoantibody Specificities to Forecast Transition to Classified SLE and Inform a Lupus Classification Risk Immune Index
Melissa Munroe¹, Rufei Lu², Timothy Gross¹, George Tsokos³, Michael Keith⁴, John Harley⁵ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, OUHSC, Oklahoma City, OK, ³BIDMC, Boston, MA, ⁴Inova, Arlington, VA, ⁵US Department of Veterans Affairs Medical Center, Cincinnati, OH
Background/Purpose: SLE is a chronic autoimmune disease driven by immune dysregulation. We have previously identified patterns of disordered immunity present prior to and concurrent with…
Abstract Number: 1483 • ACR Convergence 2021
Down-regulation of Hematopoietic Progenitor Kinase 1 by Aberrant Epigenetic Alterations in T Follicular Helper Cells Accounts for Excessive Immunity in Systemic Lupus Erythematosus
Qing Zhang¹, Huilin Zhang² and Yuming Xie¹, ¹Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China (People's Republic), ²Clinical Nursing Teaching and Research Section, Second Xiangya Hospital, Central South University, Changsha, China (People's Republic)
Background/Purpose: Recently, T follicular helper cells (Tfh cells) have been discovered to be the main CD4+ T cells assisting B cells to produce antibody. Tfh…
Abstract Number: 1502 • ACR Convergence 2021
Longitudinal Changes in B Cell Subsets in Patients in the Mesenchymal Stromal Cell Trial in Lupus: Analysis of the First Cohort
Diane Kamen¹, S Sam Lim², Scott Jenks³, Regina Bugrovosky³, Aisha Hill³, Chungwen Wei³, Cristina Drenkard³, Kenneth Kalunian⁴, Ummara Shah⁵, Mariko Ishimori⁶, Rosalind Ramsey-Goldman⁷, Saira Sheikh⁸, Mary Alison Mahieu⁷, Daniel Wallace⁹, Ellen Goldmuntz¹⁰ and Gary Gilkeson¹, ¹Medical University of South Carolina, Charleston, SC, ²Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ³Emory University, Atlanta, GA, ⁴UC San Diego, La Jolla, CA, ⁵University of Rochester, Rochester, NY, ⁶Cedars-Sinai Health System, Los Angeles, CA, ⁷Northwestern University, Chicago, IL, ⁸University of North Carolina, Chapel Hill, NC, ⁹Attune Health, Beverly Hills, CA, ¹⁰National Institutes of Health, Bethesda, MD
Background/Purpose: Recent advances allow expanded identification of B cell subtypes of pathogenic potential in lupus. Of particular interest are IgD- CD27- double negative (DN2) B…
Abstract Number: 1711 • ACR Convergence 2021
Increasing Preeclampsia Knowledge in SLE with a Specific Educational Tool: Preliminary Results
Joo Young (Esther) Lee¹, Arielle Mendel², Isabelle Malhamé², Sasha Bernatsky¹ and Evelyne Vinet³, ¹McGill University, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Pregnant women with systemic lupus erythematosus (SLE) are at high risk of preeclampsia, leading to substantial maternal and fetal morbidity. Aspirin reduces preeclampsia risk…
Abstract Number: 1743 • ACR Convergence 2021
Whole Blood Hydroxychloroquine Levels Do Not Correlate with QTc Intervals in a Cohort of 84 SLE Patients: Evidence That Antimalarials Are Not Associated with Cardiac Conduction System Toxicity
Mayce Haj-Ali¹ and H. Michael Belmont², ¹NYU Grossman School of Medicine, New York, NY, ²NYU School of Medicine, New York, NY
Background/Purpose: Hydroxychloroquine (HCQ) is an antimalarial drug used in the treatment of systemic lupus erythematous (SLE). There is limited data assessing cardiac toxicity as arrhythmias…
Abstract Number: 1761 • ACR Convergence 2021
Comparison of Belimumab and Standard of Care by Inverse Probability of Treatment Weighting Analyses Based on Propensity Score in Patients with Systemic Lupus Erythematosus in the Maintenance Phase
yusuke Miyazaki¹, Shingo Nakayamada¹, Shigeru Iwata¹, Kentaro Hanami¹, Shunsuke Fukuyo¹, Koshiro Sonomoto¹, Akio Kawabe¹, Yoshino Inoue¹, Naoaki Okubo¹ and Yoshiya Tanaka², ¹The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyusyu, Fukuoka, Japan, ²University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Development of molecular-targeted agents is essential in treat-to-target treatment strategies for systemic lupus erythematosus (SLE). We analyzed the efficacy and safety of belimumab (BEL)…
Abstract Number: 1932 • ACR Convergence 2021
Identifying Clusters of Longitudinal Autoantibody Profiles Associated with Systemic Lupus Erythematosus Disease Outcomes
May Choi¹, Irene Chen², Ann Clarke³, Marvin Fritzler³, Katherine Buhler³, Murray Urowitz⁴, John Hanly⁵, Caroline Gordon⁶, Yvan St.Pierre⁷, Sang-Cheol Bae⁸, Juanita Romero-Diaz⁹, Francisco Sanchez-Guerrero¹⁰, Sasha Bernatsky¹¹, Daniel Wallace¹², David Isenberg¹³, Anisur Rahman¹⁴, Joan Merrill¹⁵, Paul R Fortin¹⁶, Dafna Gladman¹⁷, Ian N. Bruce¹⁸, Michelle Petri¹⁹, Ellen Ginzler²⁰, Mary Anne Dooley²¹, Rosalind Ramsey-Goldman²², Susan Manzi²³, Andreas Jnsen²⁴, Graciela Alarcn²⁵, Ronald van Vollenhoven²⁶, Cynthia Aranow²⁷, Meggan Mackay²⁷, Guillermo Ruiz-Irastorza²⁸, S Sam Lim²⁹, Murat Inanc³⁰, Kenneth Kalunian³¹, Sren Jacobsen³², Christine Peschken³³, Diane Kamen³⁴, Anca Askanase³⁵, David Sontag² and Karen Costenbader³⁶, ¹Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ²Massachusetts Institute of Technology, Cambridge, MA, ³University of Calgary, Calgary, AB, Canada, ⁴Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁵Dalhousie University, Halifax, NS, Canada, ⁶Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁷Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁸Hanyang University Medical Center, Seoul, Republic of Korea, ⁹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, ¹⁰University Health Network/Sinai Health system, Toronto, ON, Canada, ¹¹McGill University, Montréal, QC, Canada, ¹²Cedars-Sinai, Los Angeles, CA, ¹³Centre for Rheumatology, University College London, London, United Kingdom, ¹⁴University College London, London, United Kingdom, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹⁷Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ¹⁸University of Manchester, Manchester, United Kingdom, ¹⁹Johns Hopkins University School of Medicine, Baltimore, MD, ²⁰SUNY Downstate Health Sciences University, Brooklyn, NY, ²¹Raleigh Neurology Associates, Chapel Hill, NC, ²²Northwestern University, Chicago, IL, ²³Allegheny Health Network, Wexford, PA, ²⁴Lund University, Lund, Sweden, ²⁵University of Alabama at Birmingham, Birmingham, AL, ²⁶Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²⁷Feinstein Institutes for Medical Research, Manhasset, NY, ²⁸Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, ²⁹Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ³⁰Istanbul University Faculty of Medicine, Istanbul, Turkey, ³¹UC San Diego, La Jolla, CA, ³²Copenhagen Lupus and Vasculitis Clinic, Centre for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ³³University of Manitoba, Winnipeg, MB, Canada, ³⁴Medical University of South Carolina, Charleston, SC, ³⁵Columbia University Medical Center, New York, NY, ³⁶Brigham and Women's Hospital, Belmont, MA
Background/Purpose: Prior studies of SLE clusters based on autoantibodies have utilized cross-sectional data from single centers. We applied clustering techniques to longitudinal and comprehensive autoantibody…
Abstract Number: 0076 • ACR Convergence 2021
Predicting the Transitions Between Lupus Anticoagulant Status and Thrombosis in SLE Using a Multi-state Markov Model
Selcan Demir¹, Jessica Li², Laurence Magder³ and Michelle Petri⁴, ¹Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Antiphospholipid syndrome (APS) is a significant cause of morbidity and mortality in patients with SLE and lupus anticoagulant (LAC) positivity is the best predictor…
Abstract Number: 0267 • ACR Convergence 2021
Psychosocial and Health Measures in Systemic Lupus Erythematosus: Before and During the COVID-19 Pandemic in the Georgian’s Organized Against Lupus Cohort
Charmayne Dunlop-Thomas¹, Gaobin Bao¹, S Sam Lim² and Cristina Drenkard¹, ¹Emory University, Atlanta, GA, ²Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Disruptions of routines or livelihood and worry during the COVID-19 pandemic may have impacted systemic lupus erythematosus (SLE) patients in multiple ways. We explored…
Abstract Number: 0338 • ACR Convergence 2021
Serum and Urine Galectin-9, IP-10 and SIGLEC-1 as Biomarkers of Disease Activity in Patients with Systemic Lupus Erythematosus
Safak Mirioglu¹, Suzan Cinar², Omer Uludag³, Erdem Gurel³, Sibel Varelci³, Yasemin Ozluk⁴, Isin Kilicaslan⁴, Yasemin Yalcinkaya⁵, Halil Yazici⁶, Ahmet Gül³, Murat Inanc⁷ and Bahar Esen⁵, ¹Division of Nephrology, Bezmialem Vakif University School of Medicine, Istanbul, Turkey, ²Department of Immunology, Istanbul University Aziz Sancar Institute of Experimental Medicine, Istanbul, Turkey, ³Division of Rheumatology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, ⁴Department of Pathology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, ⁵Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ⁶Division of Nephrology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, ⁷Istanbul University Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Galectin-9, interferon-inducible protein-10 (IP-10) and sialoadhesin (SIGLEC-1) are proteins associated with interferon signature, and considered as potential biomarkers reflecting disease activity in patients with…
Abstract Number: 0464 • ACR Convergence 2021
The Impact of Timely Post-Discharge Follow-up on Readmission Risk Among Patients with Systemic Lupus Erythematosus
Maria Schletzbaum¹, Nadia Sweet², W Ryan Powell², Andrea Gilmore Bykovskyi³, Farah Kaiksow², Ann Sheehy², Amy Kind² and Christie Bartels², ¹University of Wisconsin School of Medicine and Public Health, Middleton, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI, ³University of Wisconsin - Madison School of Nursing, Madison, WI
Background/Purpose: Systemic lupus erythematosus (SLE) has the 6th highest hospital readmission rate of all US chronic diseases with significant health disparities and costs. Transitional care…
Abstract Number: 0595 • ACR Convergence 2021
Lupus Nephritis Disparities Amongst Hospitalizations in the United States: A National Inpatient Sample Study
Sonia Gupta, Koree Willer, Amir Begovic, Mitch Waters, Laura Tarantino, Olufunmilayo Badejo, Ryan Walters and Theresa Townley, Creighton University School of Medicine, Omaha, NE
Background/Purpose: Black, Hispanic, and Native American populations in the US experience increased morbidity and mortality from systemic lupus erythematosus (SLE), with higher rates and worse…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].